iJOBS Career Panel: Contract Research Organizations

Tuesday, January 29, 2019
4:30-6pm
Deans Conference Room 123
Robert Wood Johnson Medical School
Piscataway



Bill Hanlon, Ph.D.
Group President, Clinical Development and Commercialization Services at Covance, LabCorp's drug development business.
Covance
William.Hanlon@Covance.com

Dr. Hanlon has been an active contributor to the development of innovative new medicines for almost 30 years, holding positions of increasing scientific leadership and responsibility. Trained as a biochemist and cell biologist, earning his doctorate from RWJMS and Rutgers Graduate School, he spent the first half of his career in drug discovery, identifying novel small molecules effective in targeting molecular mechanisms regulating inflammatory and immunological disease processes. For the last 15 years, Dr. Hanlon has focused on early and late clinical development as a regulatory affairs and drug development expert, advising teams of scientists how to navigate the many regulatory hurdles to develop new medicines for registration globally.

As Group President, he oversees an organization of more than 14,000 professionals with scientific, operational, regulatory, and therapeutic expertise. His previous roles at Covance include its Chief Development Officer and Head of Global Regulatory Affairs. Prior to joining Covance, Dr. Hanlon was Vice President, Head of Global Regulatory Affairs for Archimedes Pharma. Most of Dr. Hanlon's career experience was obtained over the 23 years he spent at Merck and Co. in Discovery Research, Regulatory Affairs and leading drug development programs.

Dr. Hanlon serves as a member of the Board of Trustees for the NJ Institute for Life Science Entrepreneurship (ILSE), which integrates resources to advance basic and translational research into the life sciences. He also represents the American Clinical Laboratory Association on the Governing Committee of the National Evaluation System for Health Technology Coordinating Committee (NESTcc).

Sujoy Dutta PhD
Divisional Director
Experimental Biology (BBC - PRC)
Envigo
O: 732 873 2550 Extension: 2427
M: 732 507 2961
sujoy.dutta@envigo.com

Sujoy Dutta, Ph.D., is Divisional Director of the Experimental Biology sub-division of Biomarkers, Bioanalysis and Clinical Sciences at Envigo since November 2017. Prior to this position, he held positions such as Principal Scientist at ENVIGO, Research Scientist III (Principal Investigator) at Viracor-Eurofins and Assistant Professor (Research) at the H.M. Bligh Cancer Research Center of Rosalind Franklin University of Medicine and Science. Dr. Dutta completed his Bachelor of Science in Chemistry and Master of Science in Biochemistry from University of Calcutta, Kolkata, India. In 2007, Dr. Dutta received his Doctoral degree in Microbiology and immunology from the Rosalind Franklin University of Medicine and Science (Chicago Medical School), Illinois, USA. He then pursued a postdoctoral research position at Rosalind Franklin University of Medicine and Science and later was an independent Research Faculty at the H.M. Bligh Cancer Research Center of the Rosalind Franklin University of Medicine and Science.
Dr. Dutta's area of research interest has been interactions between cancer and the immune system. Dr. Dutta joined CRO industry in 2015 and has supervised development and validation of many cell based immunoassays to support drug development at both Preclinical (non-GLP and GLP studies) and Clinical stages.



Gregory Bannish, Ph.D.
Head of Flow Cytmetry
Champions Oncology
gbannish@championsoncology.com

Greg Bannish received his Ph.D. in immunology studying MHC class II transcriptional regulation in patients with Bare Lymphocyte Syndrome at Weill Cornell university graduate school. He performed postdoctoral studies at UPENN studying B cell receptor signaling, developing a signaling protein used in adoptive transfer experiments to rescue B cell development in immunodeficient mice. He then worked at Centocor (present day Janssen) on antibody therapeutics to immunological targets, worked to increase antibody specific productivity, and candidate selection of optimal antibody drugs. He then went to Envigo for 11 years, first developing a flow cytometry, cell culture, and immunology laboratory operating under GLP regulations, developing novel

immunological methods and validated flow cytometry assays predominantly in monkey, but also human, rodent, dog, and minipig. He later became Vice President, Biopharmaceutical research for 6 years, responsible for US biological drug efforts, writing proposals and leading a team of program managers, and serving as a member of the management team. Recently, Greg joined Champions Oncology as Head of Flow Cytometry, and is developing a regulatory flow cytometry capability to support clinical trial flow cytometry, and expanding existing high-throughput preclinical flow cytometry with a focus on immune cell subset analysis to support immune oncology drug development in humanized tumor-challenged mice.

Tifani McCann, Ph.D.
Vice President
Global Head of Biostatistics and Data Analytics
Covance
Ph: 609.452.4070
Tifani.McCann@covance.com

A biometrics leader having more than 19 years of drug development experience, with 17 years at a pharmaceutical company and 2 years in the CRO industry. Receiving her Ph.D. in Biostatistics from the Medical College of Virginia, she started in industry as a project-facing statistician taking on roles of increasing responsibility over 11 years including the Immunosciences TA Head. From there she served as the Chief of Staff for the Biometrics organization and then after 15 years in Biostatistics and Statistical Programming, she expanded her skill set with an opportunity leading a Data Operations organization. After 17 years, Tifani decided it was time to again step out of her comfort zone by moving into the CRO industry and accepted a position leading Covance's Biostatistics and Statistical Programming organization. Since then her role has expanded to include Risk Based Monitoring and Medical Data Review capabilities and she currently serves as the Global Head of Biostatistics and Data Analytics at Covance. Tifani has found her 19 years working to provide solutions for patients to be incredibly rewarding and is excited to see what the next 19 years will deliver in medical advancements.

Ellen McGlinchey, Ph.D.
Research Scientist I | Study Director
Charles River Laboratories
905 Sheehy Drive, Horsham, PA 19044
P: 267.532.3865 | M: 215.443.8710 | F: 215.443.8587 ellen.mcglinchey@crl.com | www.criver.com

Research Scientist / Study Director, Charles River Laboratories, Horsham PA.
Dr. Ellen McGlinchey received her undergraduate degree in biological sciences with a minor in psychology from Connecticut College in New London, CT. Upon graduation in 2007, she joined Charles River Laboratories in Horsham, PA as a Research Technician and as an Assistant Behavioral Coordinator.
In 2011, Dr. McGlinchey went to obtain a doctorate degree at the Medical University of South Carolina in Charleston, SC, but then moved with the lab of Dr. Gary Aston-Jones to finish her last year of research at Rutgers University. She used pharmacogenetics to identify neural circuits that initiate relapse behavior in an animal model of cocaine addiction. Dr. McGlinchey was awarded a prestigious grant from the National Institute of Drug Abuse that provided her with independent funding during her graduate degree. She published her results in high-impact journals including Neuropsychopharmacology, Journal of Neuroscience, and Nature Neuroscience. Dr. McGlinchey earned a Ph.D. in Neuroscience in June 2016 from the Medical University of South Carolina.
Dr. McGlinchey returned to Charles River Laboratories as a Research Scientist and Study Director in August 2016 where she manages the technical conduct of nonclinical laboratory studies; most notably, developmental and reproductive toxicology [DART] and juvenile toxicology studies. She also interprets, analyzes, documents, and reports scientific results, ensures compliance with protocols, regulatory guidelines, and standard operating procedures, and interacts with clients. Dr. McGlinchey recently accepted a position as a Senior Research Scientist II at Gilead Sciences in Foster City, CA where she will be the compound lead toxicologist and designing safety studies to ensure safe therapeutics for people. Dr. McGlinchey has been a member of the Society for Neuroscience (SfN), the American Association for the Advancement in Science (AAAS), the Middle Atlantic Reproduction and Teratology Association (MARTA), and the Teratology Society